Collaborations with SOPHiA GENETICS, The University of Cambridge
and Optellum are intended expand access to the latest and most
advanced technologies for cancer care
GE Healthcare announced collaborations with SOPHiA GENETICS, The
University of Cambridge and Optellum as part of its vision to
advance care, make precision health more accessible, and ultimately
improve outcomes for cancer patients.
These alliances are intended to help GE Healthcare support
integrated health systems at the local level by providing the
technology to deploy software across imaging networks and helping
to make the newest innovations accessible across the broader
population. It is hoped this will enable local oncologists and
medical experts to deliver earlier diagnoses and more accurate
treatments — a crucial component in achieving positive health
outcomes with cancer patients.
“Cross-functional partnerships between organizations are key to
the creation of new approaches and intelligent tools that enable
cancer to be detected as early as possible and with the greatest
degree of accuracy,” said Dr. Ben Newton, Global Head of Oncology
Solutions at GE Healthcare. “By partnering with SOPHiA GENETICS,
Optellum, and the University of Cambridge, we’re looking to create
a more powerful oncology care pathway that promotes high-quality,
personalized, and effective medical care.”
GE Healthcare's comprehensive diagnostic imaging and monitoring
portfolio can be deployed throughout the patient's cancer journey,
from initial screening and diagnosis, through therapy guidance
facilitating minimally invasive treatment, to monitoring patient
progress.
As cases of cancer continue to rise and are predicted to reach
29.5 million new cases per year by 20401 there is a growing demand
for data-driven medicine, both for clinical practice and clinical
trials. GE Healthcare is utilizing its Edison platform to integrate
data from diverse sources, such as electronic health records (EHR)
and radiology information systems (RIS), imaging and other medical
device data. This integrated data can be used to develop and deploy
AI enabled solutions to help simplify oncology patient workflows,
better understand increasingly complicated clinical patient data,
and compare data from patient to patient.
SOPHiA GENETICS and GE Healthcare will be collaborating on
opportunities in the healthcare market, including various
initiatives and projects in the fields of digital oncology and
radiogenomic analysis. The companies will initially work together
on the creation of infrastructure to integrate data between GE’s
Edison platform and the SOPHiA DDM™ platform, as well as
co-marketing and pilot site recruitment across oncology and
radiogenomics.
The companies will be deploying GE Healthcare’s extensive
medical imaging and monitoring capabilities and Edison
platform-enabled data aggregation with the SOPHiA DDM™ cloud-based
software-as-a-service analytics genomic insights platform and
related solutions, which are available in more than 750 hospitals,
laboratories and biopharma companies.
The University of Cambridge, Cambridge University Hospitals and
GE Healthcare have agreed to collaborate on developing an
application aiming to improve cancer care, with Cambridge providing
clinical expertise and data to support GE Healthcare’s development
and evaluation of an AI-enhanced application that integrates cancer
patient data from multiple sources into a single interface.
Building on research supported by The Mark Foundation for Cancer
Research and Cancer Research UK, the collaboration aims to address
the problems of fragmented or siloed data and disconnected patient
information, which is challenging for clinicians to manage
effectively and can prevent cancer patients receiving optimal
treatment.
UK-based company Optellum is a leader in AI- decision support
for the early diagnosis and optimal treatment of lung cancer.
Together, the companies are seeking to address one of the largest
challenges in the diagnosis of lung cancer, helping providers to
determine the malignancy of a lung nodule: a suspicious lesion that
may be benign or cancerous. The majority of incidentally detected
pulmonary nodules present an indeterminate cancer risk, which are
incredibly challenging for clinicians to diagnose and manage,
leading to delayed treatment for cancer patients and invasive
procedures on healthy people.
Optellum’s Virtual Nodule Clinic identifies and scores the
probability of malignancy in a lung nodule, which is key to
determining whether biopsy is necessary, and accelerating
diagnosis. It is the only FDA-cleared AI-assisted diagnosis
software for early-stage lung cancer2, and has been shown to
improve the sensitivity and specificity of malignancy assessments
of indeterminate nodules 3 — enabling pulmonologists and
radiologists to make optimal clinical decisions4.
About GE Healthcare:
GE Healthcare is the $17 billion* healthcare business of GE
(NYSE: GE). As a leading global medical technology, pharmaceutical
diagnostics and digital solutions innovator, GE Healthcare enables
clinicians to make faster, more informed decisions through
intelligent devices, data analytics, applications and services,
supported by its Edison intelligence platform. With over 100 years
of healthcare industry experience and around 47,000 employees
globally, the company operates at the center of an ecosystem
working toward precision health, digitizing healthcare, helping
drive productivity and improve outcomes for patients, providers,
health systems and researchers around the world.
Follow us on Facebook, LinkedIn, Twitter, and Insights for the
latest news, or visit our website www.gehealthcare.com for more
information.
*Excluding BioPharma
About SOPHiA GENETICS
SOPHiA GENETICS is a healthcare technology company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
more than 780 hospital, laboratory, and biopharma institutions
globally. More info: SOPHiAGENETICS.COM; follow @SOPHiAGENETICS on
Twitter.
About Optellum
Optellum is a commercial-stage lung health company providing
Artificial Intelligence decision support software that assists
physicians in early diagnosis and optimal treatment for their
patients. The company was founded so that every lung disease
patient is diagnosed and treated at the earliest possible stage,
when chances of cure are the highest. Optellum has headquarters at
the Oxford Centre for Innovation in Oxford, United Kingdom and a
U.S. office at the Texas Medical Center in Houston, TX. For more
information, visit optellum.com.
About The University of Cambridge
The University of Cambridge is one of the world’s top ten
leading universities, with a rich history of radical thinking
dating back to 1209. Its mission is to contribute to society
through the pursuit of education, learning and research at the
highest international levels of excellence.
The University comprises 31 autonomous Colleges and 150
departments, faculties and institutions. Its 24,450 student body
includes more than 9,000 international students from 147 countries.
In 2020, 70.6% of its new undergraduate students were from state
schools and 21.6% from economically disadvantaged areas.
Cambridge research spans almost every discipline, from science,
technology, engineering and medicine through to the arts,
humanities and social sciences, with multi-disciplinary teams
working to address major global challenges. Its researchers provide
academic leadership, develop strategic partnerships and collaborate
with colleagues worldwide.
The University sits at the heart of the ‘Cambridge cluster’, in
which more than 5,300 knowledge-intensive firms employ more than
67,000 people and generate £18 billion in turnover. Cambridge has
the highest number of patent applications per 100,000 residents in
the UK.
www.cam.ac.uk
About Cambridge University Hospitals:
Cambridge University Hospitals NHS Foundation Trust (CUH) is one
of the largest and best known trusts in the country, delivering
high-quality patient care through Addenbrooke’s and the Rosie
Hospitals. CUH is a leading national centre for specialist
treatment for rare or complex conditions and a university teaching
hospital with a worldwide reputation.
CUH is a key partner in Cambridge University Health Partners
(CUHP), one of only six academic health science centres in the UK,
and is at the heart of the development of the Cambridge Biomedical
Campus (CBC), which brings together on one site world-class
biomedical research, patient care and education. As part of the
Campus development, Papworth Hospital has created a bespoke,
purpose-built hospital, and AstraZeneca is building a new global
R&D centre and corporate headquarters. The Campus is one of the
Government’s National Institute for Health Research (NIHR)
comprehensive biomedical research centres.
About The Mark Foundation Institute for Integrated Cancer
Medicine:
The Mark Foundation Institute for Integrated Cancer Medicine
(MFICM) at the University of Cambridge aims to revolutionise cancer
care by using cutting edge analytics to maximise the use of
diverse, high-volume data sets. The virtual institute exploits
recent advances in machine learning and big data technology to
capture, integrate, and derive insight into clinical, genomic and
imaging data collated from hundreds of cancer patients in real
time. Laboratory and clinic-based researchers and data experts are
working together to develop sophisticated computational integration
of these diverse data types into a single platform which can inform
and predict the best treatment decisions for each individual
patient.
MFICM is jointly funded by The Mark Foundation for Cancer
Research and Cancer Research UK Cambridge Centre. The Mark
Foundation for Cancer Research is dedicated to accelerating cures
for cancer by integrating discoveries in biology with innovative
technology. The Foundation pursues its mission by funding a global
portfolio of ground-breaking research carried out by individual
investigators, multi-investigator teams, and inter-institutional
collaborations.
Visit our websites to find out more:
www.integratedcancermedicine.org and
www.crukcambridgecentre.org.uk
About Cancer Research UK:
- Cancer Research UK is the world’s leading cancer charity
dedicated to saving lives through research.
- Cancer Research UK’s pioneering work into the prevention,
diagnosis and treatment of cancer has helped save millions of
lives.
- Cancer Research UK has been at the heart of the progress that
has already seen survival in the UK double in the last 40
years.
- Today, 2 in 4 people survive their cancer for at least 10
years. Cancer Research UK’s ambition is to accelerate progress so
that by 2034, 3 in 4 people will survive their cancer for at least
10 years.
- Cancer Research UK supports research into all aspects of cancer
through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's
vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to
find out how to support the charity, please call 0300 123 1022 or
visit www.cancerresearchuk.org. Follow us on Twitter and
Facebook.
1 https://www.cancer.gov/about-cancer/understanding/statistics
2T Health
https://eithealth.eu/news-article/eit-health-supported-optellum-marks-ai-world-first/
3 Massion PP, Antic S, Ather S, et al. Assessing the Accuracy of a
Deep Learning Method to Risk Stratify Indeterminate Pulmonary
Nodules. Am J Respir Crit Care Med. 2020 Jul 15;202(2):241-249.
https://www.atsjournals.org/doi/full/10.1164/rccm.201903-0505OC
4chani A, Massion P, Munden R, Gleeson F, Bellinger C, Dotson T,
Freitag L, Imaging AI/”Radiomics” decision support improves
physicians’ stratification of indeterminate pulmonary nodules: A
Multiple-Reader Multiple-Case study presented to The ACS National
Lung Cancer Roundtable (NLCRT) 2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211130005754/en/
Hannah Huntly hannah.huntly@ge.com +44 7887 824201
GE Aerospace (NYSE:GE)
過去 株価チャート
から 3 2024 まで 4 2024
GE Aerospace (NYSE:GE)
過去 株価チャート
から 4 2023 まで 4 2024